96
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment

, , &
Pages 149-155 | Published online: 08 Aug 2016

References

  • KleinDJThornCFDestaZFlockhartDAAltmanRBKleinTEPharmGKB summary: tamoxifen pathway, pharmacokineticsPharmacogenet Genomics2013231164364723962908
  • SaladoresPHPrechtJCSchrothWBrauchHSchwabMImpact of metabolizing enzymes on drug response of endocrine therapy in breast cancerExpert Rev Mol Diagn201313434936523638818
  • RaeJMDrurySHayesDFCYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patientsJ Natl Cancer Inst2012104645246022395643
  • KarleJBolbrinkerJVoglSInfluence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancerBreast Cancer Res Treat2013139255356023686417
  • ReganMMLeyland-JonesBBouzykMCYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trialJ Natl Cancer Inst2012104644145122395644
  • WestbrookKStearnsVPharmacogenomics of breast cancer therapy: an updatePharmacol Ther2013139111123500718
  • BinkhorstLMathijssenRHJGhobadi Moghaddam-HelmantelIMQuantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometryJ Pharm Biomed Anal20115651016102321872414
  • ChamnanphonMPechatananKSirachainanEAssociation of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifenPharmacogenomics Pers Med2013613748
  • SensornISirachainanEChamnanphonMAssociation of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifenPharmacogenomics Pers Med2013619398
  • LumDWKPerelPHingoraniADHolmesMVCYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysisPLoS One2013810e7664824098545
  • ProvinceMAGoetzMPBrauchHCYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populationsClin Pharmacol Ther201495221622724060820
  • MadlenskyLNatarajanLTchuSTamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomesClin Pharmacol Ther201189571872521430657
  • GjerdeJGeislerJLundgrenSAssociations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancerBMC Cancer201010131320565970
  • LimJSChenXASinghOImpact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patientsBr J Clin Pharmacol201171573775021480951
  • TehLKMohamedNISallehMZThe risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1AAPS J2012141525922183189
  • AreepiumNPanomvanaDRungwanonchaiPSathapornSVoravudNEffects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patientsBreast Cancer (Dove Med Press)20135737824648760
  • Zafra-CeresMde HaroTFarez-VidalEInfluence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancerInt J Med Sci201310793293723781139
  • MürdterTESchrothWBacchus-GerybadzeLActivity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasmaClin Pharmacol Ther2011895110
  • BarginearMFJaremkoMPeterIIncreasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity scoreClin Pharmacol Ther201190460561121900890
  • RatainMJNakamuraYCoxNJCYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological qualityClin Pharmacol Ther201394218518723872831
  • HertzDLMcLeodHLIrvinWJJrTamoxifen and CYP2D6: a contradiction of dataOncologist201217562063022531359
  • ZangerUMSchwabMCytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variationPharmacol Ther2013138110314123333322
  • TehLKBertilssonLPharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importanceDrug Metab Pharmacokinet2012271556722185816
  • Fernández-SantanderAGaibarMNovilloARelationship between genotypes SULT1A2 and CYP2D6 and tamoxifen metabolism in breast cancer patientsPLoS One201387e7018323922954
  • LyonEGastier FosterJPalomakiGELaboratory testing of CYP2D6 alleles in relation to tamoxifen therapyGenet Med20121412990100022955113
  • GaedigkAComplexities of CYP2D6 gene analysis and interpretationInt Rev Psychiatry201325553455324151800